Featured/ OMER/ 10/15/2025 · 9:20 AM Omeros Strikes $2.1 Billion Deal, Granting Novo Nordisk Exclusive Global Rights to Zaltenibart Novo Nordisk acquired the rare disease drug zaltenibart from Omeros for up to $2.1B. It treats disorders like PNH & Novo plans Phase 3.